Revance Therapeutics (RVNC) Short Interest Ratio & Short Volume → is this a buy and hold stock? (From Tips4Traders) (Ad) Free RVNC Stock Alerts $3.48 +0.16 (+4.82%) (As of 05/14/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Revance Therapeutics Short Interest DataCurrent Short Volume12,290,000 sharesPrevious Short Volume11,630,000 sharesChange Vs. Previous Month+5.67%Dollar Volume Sold Short$44.37 millionShort Interest Ratio / Days to Cover6.7Last Record DateApril 30, 2024Outstanding Shares104,450,000 sharesPercentage of Shares Shorted11.77%Today's Trading Volume3,957,764 sharesAverage Trading Volume2,173,230 sharesToday's Volume Vs. Average182% Short Selling Revance Therapeutics ? Sign up to receive the latest short interest report for Revance Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatRVNC Short Interest Over TimeRVNC Days to Cover Over TimeRVNC Percentage of Float Shorted Over Time Ad Monetary GoldTrump Reveals Conspiracy Behind Fed-Controlled Digital Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. Revance Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202412,290,000 shares $44.37 million +5.7%N/A6.7 $3.61 4/15/202411,630,000 shares $46.17 million -14.2%N/A6.5 $3.97 3/31/202413,550,000 shares $66.67 million +24.7%N/A7.5 $4.92 3/15/202410,870,000 shares $57.67 million -8.5%N/A6.1 $5.31 2/29/202411,880,000 shares $84.82 million -3.7%N/A6.9 $7.14 2/15/202412,340,000 shares $68.86 million -2.5%N/A8.5 $5.58 Get the Latest News and Ratings for RVNC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/202412,650,000 shares $63.63 million -14.6%N/A7.7 $5.03 1/15/202414,810,000 shares $87.97 million +2.9%N/A9 $5.94 12/31/202314,390,000 shares $126.49 million +16.1%N/A8.4 $8.79 12/15/202312,400,000 shares $100.19 million -5.1%N/A7.3 $8.08 11/30/202313,070,000 shares $88.48 million -10.7%N/A6.2 $6.77 11/15/202314,630,000 shares $102.70 million +13.2%N/A7.1 $7.02 10/31/202312,930,000 shares $102.02 million -11.2%N/A6.5 $7.89 10/15/202314,560,000 shares $125.80 million -8.5%N/A7.5 $8.64 9/30/202315,910,000 shares $182.49 million +12.0%N/A8.8 $11.47 9/15/202314,200,000 shares $238.56 million -0.8%N/A7.9 $16.80 8/31/202314,310,000 shares $252.29 million No ChangeN/A10.2 $17.63 8/15/202314,310,000 shares $269.03 million +1.4%N/A10.5 $18.80 7/31/202314,120,000 shares $333.66 million +8.3%N/A10.1 $23.63 7/15/202313,040,000 shares $293.53 million -13.1%N/A10.1 $22.51 6/30/202315,000,000 shares $379.65 million +3.0%N/A11.1 $25.31 6/15/202314,560,000 shares $417.87 million -3.8%N/A11.2 $28.70 5/31/202315,130,000 shares $462.37 million +2.8%N/A11.8 $30.56 5/15/202314,720,000 shares $498.42 million +4.9%N/A10.8 $33.86 4/30/202314,030,000 shares $446.57 million +7.0%N/A11.1 $31.83 4/15/202313,110,000 shares $398.68 million +1.5%N/A10.1 $30.41 3/31/202312,920,000 shares $416.15 million +3.5%N/A8.3 $32.21 3/15/202312,480,000 shares $382.51 million +2.5%N/A7.9 $30.65 2/28/202312,180,000 shares $422.65 million +10.9%N/A7.9 $34.70 2/15/202310,980,000 shares $364.65 million -4.7%N/A7.5 $33.21 1/31/202311,520,000 shares $399.51 million -12.6%N/A7.6 $34.68 1/15/202313,180,000 shares $367.99 million +0.9%N/A8.7 $27.92 12/30/202213,060,000 shares $241.09 million +29.4%N/A9 $18.46 12/15/202210,090,000 shares $216.94 million -0.1%N/A7.9 $21.50 11/30/202210,100,000 shares $219.27 million -1.4%N/A6.6 $21.71 11/15/202210,240,000 shares $243.30 million +7.1%N/A6.2 $23.76 10/31/20229,560,000 shares $213.28 million +0.4%14.0%6 $22.31 10/15/20229,520,000 shares $238.95 million +1.6%13.9%6.4 $25.10 9/30/20229,370,000 shares $252.99 million +16.5%13.8%7 $27.00 9/15/20228,040,000 shares $212.34 million +3.7%11.8%6.9 $26.41is this a buy and hold stock? (Ad)“Simply Wall Street” LOVES this stock as a Buy and Hold. It’s surging now! ….Click here to learn more RVNC Short Interest - Frequently Asked Questions What is Revance Therapeutics' current short interest? Short interest is the volume of Revance Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 12,290,000 shares of RVNC short. Learn More on Revance Therapeutics' current short interest. What is a good short interest ratio for Revance Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RVNC shares currently have a short interest ratio of 7.0. Learn More on Revance Therapeutics's short interest ratio. Which institutional investors are shorting Revance Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Revance Therapeutics: Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Revance Therapeutics' short interest increasing or decreasing? Revance Therapeutics saw a increase in short interest in April. As of April 30th, there was short interest totaling 12,290,000 shares, an increase of 5.7% from the previous total of 11,630,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Revance Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Revance Therapeutics: Acelyrin, Inc. (13.90%), PepGen Inc. (1.66%), Theravance Biopharma, Inc. (14.10%), Esperion Therapeutics, Inc. (11.79%), Entrada Therapeutics, Inc. (9.54%), Fulcrum Therapeutics, Inc. (4.83%), Neurogene Inc. (8.85%), Lexicon Pharmaceuticals, Inc. (9.52%), Korro Bio, Inc. (2.68%), Heron Therapeutics, Inc. (18.11%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Revance Therapeutics stock? Short selling RVNC is an investing strategy that aims to generate trading profit from Revance Therapeutics as its price is falling. RVNC shares are trading up $0.16 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Revance Therapeutics? A short squeeze for Revance Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RVNC, which in turn drives the price of the stock up even further. How often is Revance Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RVNC, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Acelyrin Short Interest Data PepGen Short Interest Data Theravance Biopharma Short Interest Data Esperion Therapeutics Short Interest Data Entrada Therapeutics Short Interest Data Fulcrum Therapeutics Short Interest Data Neurogene Short Interest Data Lexicon Pharmaceuticals Short Interest Data Korro Bio Short Interest Data Heron Therapeutics Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RVNC) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldForget the “Magnificent 7” Tech Companies, Buy This AI Stock InsteadBanyan Hill Publishingis this a buy and hold stock?Tips4TradersWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersBiden to Drop BOMBSHELL June 13th?Paradigm Press